Alamar Biosciences Business Summary

Alamar Biosciences, Inc. (ALMR) is a commercial-stage precision proteomics company that generates revenue through a high-utilization "razor-and-blade" model, selling its proprietary ARGO HT Systems alongside a recurring stream of high-margin consumables and specialized laboratory services. The company’s primary business segment centers on its NULISA (Nucleic Acid-Linked Immuno-Sandwich Assay) technology, which enables ultra-high sensitivity protein detection at the attomolar level for early disease diagnosis, particularly in neurodegeneration and oncology. Revenue is diversified across instrument sales, multiplex assay kits, and service-based biomarker discovery for a global base of biopharmaceutical and academic clients. Within the competitive landscape, Alamar competes directly with Quanterix, Olink (Thermo Fisher Scientific), SomaLogic (Standard BioTools), and Seer, positioning itself as the market leader in sensitivity for low-abundance biomarkers, such as pTau217 for Alzheimer’s disease. The company was founded by a team of industry veterans led by Chairman and CEO Yuling Luo, PhD, a serial entrepreneur who previously co-founded Advanced Cell Diagnostics and invented the RNAscope technology. The executive leadership includes President Tod White, JD, and CFO Justin McAnear, who previously served as CFO of 10x Genomics and held senior finance roles at Tesla and Apple. Technical direction is provided by Co-founder and COO Steve Chen, PhD, and CTO Xiao-Jun Ma, PhD, while scientific strategy is led by CSO Stephen Williams, MD, PhD, formerly of SomaLogic. Alamar is supported by a robust investor base including Illumina Ventures, Sands Capital, and T. Rowe Price, with a board of directors that includes industry leaders like Rebecca Chambers and Nicholas Naclerio.